ArticleToxicological research2018
Protective Effect of Isoliquiritigenin against Ethanol-Induced Hepatic Steatosis by Regulating the SIRT1-AMPK Pathway.
Article in Toxicological research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Reducing effects of isoliquiritigenin, a naturally occurring GABAPsychopharmacology · 2026Article
- Article
- Oxidative stress in a cellular model of alcohol-related liver disease: protection using curcumin nanoformulations.Scientific reports · 2025Article
- Therapeutic potential of traditional Chinese medicine in pancreatic fibrosis: mechanisms of TCM formulas and active ingredients.Frontiers in pharmacology · 2025Review
- Flavonoids in natural products for the therapy of liver diseases: progress and future opportunities.Frontiers in pharmacology · 2024Review
- AXL is required for hypoxia-mediated hypoxia-inducible factor-1 alpha function in glioblastoma.Toxicological research · 2023Article
- Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Cheong-sang-bang-pung-san alleviated hepatic lipid accumulation by regulating lipid metabolismFrontiers in pharmacology · 2023Article
- Inhibitory Effect of Isoliquiritigenin in Niemann-Pick C1-Like 1-Mediated Cholesterol Uptake.Molecules (Basel, Switzerland) · 2022Article
- Hepatoprotective effect of Trigonella foenum graecum against ethanol-induced cell death in human liver cells (HepG2 and Huh7).Molecular biology reports · 2022Article
- Astragaloside alleviates alcoholic fatty liver disease by suppressing oxidative stress.The Kaohsiung journal of medical sciences · 2021Article
- Isoliquiritigenin, an active ingredient of Glycyrrhiza, elicits antinociceptive effects via inhibition of NaNaunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Perspectives on the Role of Isoliquiritigenin in Cancer.Cancers · 2021Review
- Isoliquiritigenin downregulates miR-195 and attenuates oxidative stress and inflammation in STZ-induced retinal injury.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Isoliquiritigenin ameliorates caerulein-induced chronic pancreatitis by inhibiting the activation of PSCs and pancreatic infiltration of macrophages.Journal of cellular and molecular medicine · 2020Article
- Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.Frontiers in oncology · 2020Article
- Solid-State Fermentation ofEvidence-based complementary and alternative medicine : eCAM · 2020Article
- The Beneficial Roles of SIRT1 in Drug-Induced Liver Injury.Oxidative medicine and cellular longevity · 2019Review
- Aldose Reductase Inhibitors of Plant Origin in the Prevention and Treatment of Alcoholic Liver Disease: A Minireview.BioMed research international · 2019Review
- Isoliquiritigenin Inhibits Cigarette Smoke-Induced COPD by Attenuating Inflammation and Oxidative Stress via the Regulation of the Nrf2 and NF-κB Signaling Pathways.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethanol-induced fat accumulation, the earliest and most common response of the liver to ethanol exposure, may be involved in the pathogenesis of liver diseases. Isoliquiritigenin (ISL), an important constituent of Glycyrrhizae Radix, is a chalcone derivative that exhibits antioxidant, anti-inflammatory, and phytoestrogenic activities. However, the effect of ISL treatment on lipid accumulation in hepatocytes and alcoholic hepatitis remains unclear. Therefore, we evaluated the effect and underlying mechanism of ISL on ethanol-induced hepatic steatosis by treating AML-12 cells with 200 mM ethanol and/or ISL (0~50 μM) for 72 hr. Lipid accumulation was assayed by oil red O staining, and the expression of sirtuin1 (SIRT1), sterol regulatory element-binding protein-1c (SREBP-1c), AMP-activated protein kinase (AMPK), and peroxisome proliferator-activated receptor alpha (PPARα) was studied by western blotting. Our results indicated that ISL treatment upregulated SIRT1 expression and downregulated SREBP-1c expression in ethanol-treated cells. Similarly, oil red O staining revealed a decrease in ethanol-induced fat accumulation upon co-treatment of ethanol-treated cells with 10, 20, and 50 μM of ISL. These findings suggest that ISL can reduce ethanol induced-hepatic lipogenesis by activating the SIRT1-AMPK pathway and thus improve lipid metabolism in alcoholic fatty livers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.